24/7 Market News Snapshot 15 July, 2025 – ProKidney Corp. Class A Ordinary Shares (NASDAQ:PROK)

July 15, 2025

DENVER, Colo., 15 July, 2025 (www.247marketnews.com) – (NASDAQ:PROK) are discussed in this article.
ProKidney Corp. is witnessing a significant surge in its stock value, reflecting a heightened investor interest fueled by recent positive developments. In pre-market trading, shares of ProKidney soared by 28.7%, reaching $4.749 from the previous close of $3.690, supported by a strong trading volume of 4.17 million shares. This momentum highlights market confidence as analysts closely follow the stock’s performance, awaiting the market’s official opening.

In tandem with the stock’s positive trajectory, ProKidney has announced a pivotal advancement in its innovative approach to treating chronic kidney disease (CKD). Following a Type B meeting with the U.S. Food and Drug Administration (FDA), the agency has endorsed the use of the slope of estimated glomerular filtration rate (eGFR) as a suitable surrogate endpoint for the accelerated approval pathway for rilparencel, ProKidney’s pioneering autologous cell therapy. This designation positions the company for potential accelerated and full approval based on the ongoing Phase 3 PROACT 1 study.

Rilparencel, which has already secured the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation, aims to preserve kidney function in patients at increased risk of kidney failure, particularly those affected by type 2 diabetes. With nearly 50% of required participants already enrolled, the Phase 3 trial is on track to produce topline data by Q2 2027, which will be vital for the approval application.

ProKidney’s commitment to addressing the unmet medical need of CKD—impacting approximately 37 million adults—underscores its ambition to revolutionize kidney disease management. As the company advances towards its strategic objectives, it embodies hope for those facing the challenges associated with this relentless condition.

Related news for (PROK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.